ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2016; 7(1):37-41. doi:10.7150/jca.13090 This issue Cite
Research Paper
Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
1. Xiamen Cancer Center, Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China;
2. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China;
3. Biobank, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China;
4. Department of Basic Medical Science, Medical College, Xiamen University, Xiamen, People's Republic of China;
5. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Nasopharyngeal Carcinoma, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China.
* Equally contributors
Citation:
Wu SG, He ZY, Ren HY, Yang LC, Sun JY, Li FY, Guo L, Lin HX. Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer. J Cancer 2016; 7(1):37-41. doi:10.7150/jca.13090. https://www.jcancer.org/v07p0037.htm
Other stylesAbstract
Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lymph node metastasis (ALNM) in patients with breast cancer.
Methods: This retrospective study analyzed 1148 breast cancer patients whose preoperative CEA and CA 15-3 levels were measured. The association of these tumor markers and clinicopathologic parameters with ALNM was determined by univariate and multivariate analysis.
Results: A median of 15 lymph nodes were removed. Seven hundred seventy-eight (67.8%) patients had node-negative disease and 370 (32.2%) had ALNM. Univariate analysis showed that tumor location (P = 0.024), stage (P = 0.001), grade (P < 0.001), lymphovascular invasion (LVI) (P < 0.001), CEA level (P < 0.001), CA15-3 level (P < 0.001), and breast cancer subtype (BCS) (P < 0.001) were significantly associated with ALNM. ALNM was present in 4.5% of patients with normal CEA and 11.6% of patients with elevated CEA. ALNM was present in 8.0% of patients with normal CA15-3 and 17.0% of patients with high CA15-3. Multivariate logistic regression analysis showed that tumor location, stage, grade, LVI, CEA, CA15-3, and BCS were significantly and independently associated with ALNM (P < 0.05 for all).
Conclusion: The probability of ALNM was greater in patients with elevated preoperative serum levels of CEA and CA15-3. CEA and CA15-3 appear to be independent predictors of ALNM in breast cancer.
Keywords: Breast cancer, axillary lymph node metastases, CEA, CA15-3.
Citation styles
APA
Wu, S.G., He, Z.Y., Ren, H.Y., Yang, L.C., Sun, J.Y., Li, F.Y., Guo, L., Lin, H.X. (2016). Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer. Journal of Cancer, 7(1), 37-41. https://doi.org/10.7150/jca.13090.
ACS
Wu, S.G.; He, Z.Y.; Ren, H.Y.; Yang, L.C.; Sun, J.Y.; Li, F.Y.; Guo, L.; Lin, H.X. Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer. J. Cancer 2016, 7 (1), 37-41. DOI: 10.7150/jca.13090.
NLM
Wu SG, He ZY, Ren HY, Yang LC, Sun JY, Li FY, Guo L, Lin HX. Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer. J Cancer 2016; 7(1):37-41. doi:10.7150/jca.13090. https://www.jcancer.org/v07p0037.htm
CSE
Wu SG, He ZY, Ren HY, Yang LC, Sun JY, Li FY, Guo L, Lin HX. 2016. Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer. J Cancer. 7(1):37-41.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.